Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 878 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Observation only Clear all
Recruiting Phase 3 Interventional

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

NCT07776691
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
R-DXd, Bevacizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Burlington, Massachusetts • Eugene, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 11:57 AM EDT
Completed No phase listed Observational

Artificial Intelligence for Digital Cholangioscopy Neoplasia Diagnosis

NCT05147389
View directory record Official record
Conditions
Common Bile Duct Neoplasms, Non-Neoplastic Bile Duct Disorder
Interventions
AI model classification, DSOC endoscopist experts' classification
Diagnostic Test
Lead sponsor
Instituto Ecuatoriano de Enfermedades Digestivas
Other
Eligibility
18 Years to 79 Years
Enrollment
170 participants
Timeline
2020 – 2022
U.S. locations
3
States / cities
New Brunswick, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 30, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional Results available

Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

NCT03602976
View directory record Official record
Conditions
Hepatic Sarcoidosis, Elevated Alkaline Phosphatase
Interventions
Ursodeoxycholic Acid
Drug
Lead sponsor
Ethan Weinberg
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 30, 2026, 11:57 AM EDT
Withdrawn No phase listed Observational

Oral Steroid Treatment for Chronic Rhinosinusitis

NCT01255683
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
oral corticosteroid taper
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 30, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

NCT02849457
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Early Vigabatrin, Delayed Vigabatrin (Placebo)
Drug
Lead sponsor
Martina Bebin
Other
Eligibility
1 Day to 6 Months
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 30, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Progressing Home Health Rehabilitation for Older Adults

NCT02905370
View directory record Official record
Conditions
Older Adults, Physical Deconditioning
Interventions
Progressive Multi-Component (PMC), Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years to 100 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 30, 2026, 11:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

NCT02700373
View directory record Official record
Conditions
Contact Dermatitis
Interventions
PDC-APB, Placebo
Drug
Lead sponsor
Hapten Sciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 30, 2026, 11:57 AM EDT
Completed No phase listed Observational Results available

A Study of Osseotite Certain Prevail Implants Used to Support Short Fixed Bridges With Immediate Occlusal Loading.

NCT00728962
View directory record Official record
Conditions
Partial Edentulism, Tooth Disease
Interventions
Not listed
Lead sponsor
ZimVie
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 11:57 AM EDT
Recruiting Phase 1 Interventional

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

NCT05400603
View directory record Official record
Conditions
Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
Combination Product
Lead sponsor
Emory University
Other
Eligibility
12 Months and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 30, 2026, 11:57 AM EDT
Completed No phase listed Observational

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

NCT02252159
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
264
States / cities
Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 30, 2026, 11:57 AM EDT
Recruiting No phase listed Observational

Rapid-Response EEG in Children With Suspected Status Epilepticus

NCT06564662
View directory record Official record
Conditions
Status Epilepticus, Coma
Interventions
Rapid Response EEG
Device
Lead sponsor
Children's Hospital at Montefiore
Other
Eligibility
2 Years to 18 Years
Enrollment
60 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 30, 2026, 11:57 AM EDT
Completed Not applicable Interventional Results available

Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation

NCT01590875
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Adenosine arm
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Physical Therapy Exercises in Hyperkyphosis

NCT03212664
View directory record Official record
Conditions
Hyperkyphosis
Interventions
exercise
Other
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
10 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 30, 2026, 11:57 AM EDT
Completed No phase listed Observational

Study Comparing Ultrasound-guided FICNB Block to Systemic Analgesia in Treatment of Pediatric Femur Fracture

NCT05947292
View directory record Official record
Conditions
Femur Fracture
Interventions
Ultrasound-Guided Fascia Iliaca Compartment Nerve Block
Procedure
Lead sponsor
Zachary Binder
Other
Eligibility
4 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 30, 2026, 11:57 AM EDT
Completed No phase listed Observational

Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment

NCT02827214
View directory record Official record
Conditions
Thoracolumbar Burst Fracture
Interventions
Not listed
Lead sponsor
AO Innovation Translation Center
Other
Eligibility
18 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
San Diego, California • East Syracuse, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 30, 2026, 11:57 AM EDT
Active, not recruiting No phase listed Observational

Clinical Outcomes and Patient Satisfaction With Use of the Amma System

NCT05508984
View directory record Official record
Conditions
Breast Cancer
Interventions
Amma Cooling Caps
Device
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Newberg, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 30, 2026, 11:57 AM EDT
Not listed Phase 4 Interventional

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

NCT05546047
View directory record Official record
Conditions
Fibrillary Glomerulonephritis
Interventions
Acthar Gel 80 UNT/ML Injectable Solution
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Lawrenceville, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 30, 2026, 11:57 AM EDT
Recruiting No phase listed Observational

Helmsley 3.0: Abbreviated MRE

NCT06533228
View directory record Official record
Conditions
Crohn's Disease
Interventions
Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 30, 2026, 11:57 AM EDT
Recruiting Phase 2 Interventional

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

NCT06088381
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test)
Other · Radiation · Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 11:57 AM EDT
Terminated Phase 4 Interventional Results available

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 30, 2026, 11:57 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Acute Respiratory Infection Consortium

NCT01021098
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
17 Years to 55 Years
Enrollment
2,018 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 30, 2026, 11:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Improving Metabolic & Mental Health in Female Healthcare Shift Workers

NCT06158204
View directory record Official record
Conditions
Sleep, Inadequate, Overweight and Obesity, Work Related Stress, Healthy Lifestyle
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 30, 2026, 11:57 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)

NCT07530796
View directory record Official record
Conditions
Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency
Interventions
scAAV9/AGA
Genetic
Lead sponsor
Rare Trait Hope
Other
Eligibility
4 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 11:57 AM EDT
Not yet recruiting No phase listed Observational

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

NCT07499882
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
Ziconotide
Drug
Lead sponsor
Christian Hospital Northeast Northwest
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 30, 2026, 11:57 AM EDT